Healthcare Services

Atopic Dermatitis Clinical Trials Market Expected to Record Steady Growth and Approach $4.78 Billion by 2030

March 30, 2026March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Atopic Dermatitis Clinical Trials Market By 2030 Starting From Its 2026 Size?

The market size for atopic dermatitis clinical trials has expanded significantly over recent years. This market is expected to increase from $2.74 billion in 2025 to $3.07 billion in 2026, driven by a compound annual growth rate (CAGR) of 12.0%. The historical growth in this sector is linked to the rising prevalence of atopic dermatitis, the broadening of dermatology-focused drug pipelines, increased investments in clinical research, greater involvement of Contract Research Organizations (CROs) in dermatology trials, and advancements in trial design methodologies.

The atopic dermatitis clinical trials market size is projected to see substantial growth in the coming years. It is expected to expand to $4.78 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. The anticipated growth during this period can be attributed to the increasing demand for novel biologics and JAK inhibitors, the rising adoption of decentralized clinical trials, greater utilization of real-world evidence studies, the broadening of personalized treatment approaches, and an increase in regulatory approvals for advanced therapies. Key trends in the forecast period include a growing incorporation of biologic and targeted therapies into trials, the rising use of digital patient monitoring tools, a heightened focus on patient-centric trial designs, the expansion of late-phase multicenter studies, and an enhanced emphasis on long-term safety and quality of life endpoints.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27213&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Atopic Dermatitis Clinical Trials Market?

Increased pharmaceutical and biopharma investments are projected to drive the expansion of the atopic dermatitis clinical trials market. These investments represent the funding and capital allocated to the research, development, manufacturing, and commercialization of various drugs and biologic therapies. The uptick in pharmaceutical and biopharma investments is attributed to the growing need for innovative treatments, which offer precise therapeutic options and improved outcomes for patients. Such investments support atopic dermatitis clinical trials by providing financial backing for the research and rigorous testing of new therapies, thereby allowing scientists to conduct comprehensive studies that confirm their effectiveness and safety. As an illustration, in December 2024, according to the Association of Australian Medical Research Institutes (AAMRI), an Australia-based nonprofit organization, Australian medical research institutes together received approximately AUD 2.5 billion (~ USD 1.65 billion) in total revenue in 2023. Thus, the escalating pharmaceutical and biopharma investments are a key factor propelling the growth of the atopic dermatitis clinical trials market.

Which Segment Categories Define The Atopic Dermatitis Clinical Trials Market?

The atopic dermatitis clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Molecule Type: Small Molecules, Large Molecules

3) By Study Designs: Interventional, Observational

4) By Mode: Outsourced, In-House

5) By Industry: Contract Research Organizations, Pharmaceutical And Biotechnology Companies, Research And Academic Institutes

Subsegments:

1) By Phase I: Safety And tolerability studies, Dose-Escalation studies, Pharmacokinetics (PK) And Pharmacodynamics (PD) Studies

2) By Phase II: Dose-Ranging Studies, Efficacy And Safety Studies, Randomized Controlled Trials (RCTs), Biomarker Identification Studies

3) By Phase III: Large-Scale Efficacy Studies, Comparative Effectiveness Trials, Multicenter Randomized Trials, Long-Term Safety Assessment

4) By Phase IV: Post-Marketing Surveillance, Real-World Evidence Studies, Drug Utilization Studies, Health Outcomes And Quality Of Life Studies

What Trends Are Projected To Affect The Atopic Dermatitis Clinical Trials Market?

Leading companies operating in the atopic dermatitis clinical trials market are concentrating on developing innovative products, such as oral inhibitors, to maintain consistent therapeutic effects over time. Oral inhibitors are medications taken by mouth that function by obstructing specific enzymes or signaling pathways implicated in disease progression. For example, in February 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, declared that the US Food and Drug Administration had approved its supplemental New Drug Application for CIBINQO (abrocitinib). This approval broadened the drug’s usage to include adolescents aged 12 to under 18 with moderate-to-severe atopic dermatitis that has not been adequately controlled by other systemic treatments or biologics. Previously, CIBINQO had only received approval for adults 18 and older. This expansion introduces a new treatment choice for younger patients experiencing difficult-to-treat AD. The decision is supported by clinical trial data showcasing its safety and effectiveness in this demographic.

Who Are The Top Companies Competing In The Atopic Dermatitis Clinical Trials Market?

Major companies operating in the atopic dermatitis clinical trials market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis International AG, Sanofi S.A., GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Organon & Co., Charles River Laboratories International Inc., LEO Pharma A/S, QIMA Limited, Medpace Holdings Inc., Novotech Health Holdings Pte Ltd., Biocytogen Pharmaceuticals Co. Ltd., REPROCELL Inc., AnaptysBio Inc., Imavita S.A.S., Oncodesign Services S.A.S.

Read the full atopic dermatitis clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-clinical-trials-global-market-report

Which Regions Are Projected To Dominate The Atopic Dermatitis Clinical Trials Market In The Coming Years?

North America was the largest region in the atopic dermatitis clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Atopic Dermatitis Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27213&type=smp

Browse Through More Reports Similar to the Global Atopic Dermatitis Clinical Trials Market 2026, By The Business Research Company

Dermatitis Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Dermatology Global Market Report

https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report

Allergic Rhinitis Global Market Report

https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795